The Pharma Data

FEBRUARY 12, 2022

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that China’s National Medical Products Administration (NMPA) has approved Benlysta (belimumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard of care. About lupus. Benlysta China Indication.

Production 52

Production Therapies Trials Disease 52

NIH Director's Blog: Drug Development

MAY 21, 2020

Just one infusion of this combination antibody therapy lowered the amount of viral genetic material in the animals’ lungs by as much as 30 percent compared to the amount in untreated animals. Meanwhile, there’s been other impressive recent progress towards the development of monoclonal antibody therapies for COVID-19. In the U.S.

Virus 52

Virus Vaccine Laboratories Small Molecule 52

The Pharma Data

MARCH 26, 2021

The CHMP’s positive opinion brings us one step closer to providing physicians and patients in Europe with the first treatment option specifically designed to work in lupus and lupus nephritis.”. Despite improvements in both diagnosis and treatment over the last few decades, LN remains an indicator of poor prognosis. [3],

Therapies 52

Therapies Disease Treatment Vaccine 52

The Pharma Data

MAY 5, 2021

GlaxoSmithKline plc (GSK) today announced the European Commission has approved the expanded use of intravenous and subcutaneous BENLYSTA (belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis (LN) in Europe, in addition to systemic lupus erythematosus (SLE).

Therapies 52

Therapies Disease Treatment International 52

The Pharma Data

DECEMBER 23, 2020

Eligible patients enrolled in the trial receive treatment with AIM’s flagship pipeline drug Ampligen. It is approved in Argentina as the world’s first therapy for severe Chronic Fatigue Syndrome and is the only late-stage drug in the U.S. All study subjects will receive the same Ampligen treatments.

Clinical Trials 52

Clinical Trials Trials Virus International 52

The Pharma Data

JULY 22, 2021

NOTE: ADUHELM TM (aducanumab-avwa)injection 100 mg/mL solutionis indicated for the treatment of Alzheimer’s disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

Disease 52

Disease Research Clinical Trials FDA 52

Drug Target Review

NOVEMBER 30, 2023

Then I was approached to co-found AC Immune in 2003. Food and Drug Administration for our Alzheimer’s vaccine candidate, ACI-24.060. COVID-19 has shown the revolutionary impact of vaccines. Our investigational active immunisation therapies could potentially delay or perhaps even prevent the onset of clinical dementia symptoms.

Disease 95

Disease Laboratories Therapies Treatment 95